Antimalarial Drugs as Immune Modulators: New Mechanisms for Old Drugs

Literature Cited

1. Meshnick SR, Dobson MJ. 1.  2001. The history of antimalarial drugs. Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery P Rosenthal. Totowa, NJ: Humana [Google Scholar]
2. Flannery EL, Chatterjee AK, Winzeler EA. 2.  2013. Antimalarial drug discovery—approaches and progress towards new medicines. Nat. Rev. Microbiol. 11:849–62 [Google Scholar]
3. Hsu E. 3.  2006. The history of qing hao in the Chinese materia medica. Trans. R. Soc. Trop. Med. Hyg 100505–8 [Google Scholar]
4. Ehsanian R, Van Waes C, Feller SM. 4.  2011. Beyond DNA binding—a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell. Commun. Signaling 9:13 [Google Scholar]
5. Gurova K. 5.  2009. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future Oncol 5:1685–704 [Google Scholar]
6. Kar SS, Pradhan HS, Mohanta GP. 6.  2010. Concept of essential medicines and rational use in public health. Indian J. Community Med. 35:10–13 [Google Scholar]
7. Ridley RG. 7.  2002. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415:686–93 [Google Scholar]
8. Minie M, Chopra G, Sethi G. 8.  et al. 2014. CANDO and the infinite drug discovery frontier. Drug Discov. Today 19:1353–63 [Google Scholar]
9. An J, Woodward JJ, Sasaki T. 9.  et al. 2015. Cutting edge: antimalarial drugs inhibit IFN-beta production through blockade of cyclic GMP-AMP synthase-DNA interaction. J. Immunol. 194:4089–93 [Google Scholar]
10. Paddon CJ, Westfall PJ, Pitera DJ. 10.  et al. 2013. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496:528–32 [Google Scholar]
11. Hale V, Keasling JD, Renninger N. 11.  et al. 2007. Microbially derived artemisinin: a biotechnology solution to the global problem of access to affordable antimalarial drugs. Am. J. Trop. Med. Hyg 77198–202 [Google Scholar]
12. Mitchell W. 12.  2011. Natural products from synthetic biology. Curr. Opin. Chem. Biol. 15:505–15 [Google Scholar]
13. Conway DJ. 13.  2015. Paths to a malaria vaccine illuminated by parasite genomics. Trends Genet.: TIG 31:97–107 [Google Scholar]
14. Karunamoorthi K. 14.  2014. Malaria vaccine: a future hope to curtail the global malaria burden. Int. J. Prev. Med. 5:529–38 [Google Scholar]
15. de Beer TA, Wells GA, Burger PB. 15.  et al. 2009. Antimalarial drug discovery: in silico structural biology and rational drug design. Infect. Disord. Drug Targets 9:304–18 [Google Scholar]
16. Vedadi M, Lew J, Artz J. 16.  et al. 2007. Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol. Biochem. Parasitol. 151:100–10 [Google Scholar]
17. Buckee CO, Wesolowski A, Eagle NN. 17.  et al. 2013. Mobile phones and malaria: modeling human and parasite travel. Travel Med. Infect. Dis 1115–22 [Google Scholar]
18. Hay SI, George DB, Moyes CL. 18.  et al. 2013. Big data opportunities for global infectious disease surveillance. PLOS Med 10:e1001413 [Google Scholar]
19. Dlugonska H. 19.  2015. The Nobel Prize 2015 in physiology or medicine for highly effective antiparasitic drugs. Ann. Parasitol. 61:299–301 [Google Scholar]
20. Wolf R, Wolf D, Ruocco V. 20.  2000. Antimalarials: unapproved uses or indications. Clin. Dermatol. 18:17–35 [Google Scholar]
21. Baechler EC, Batliwalla FM, Karypis G. 21.  et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. PNAS 100:2610–15 [Google Scholar]
22. Bennett L, Palucka AK, Arce E. 22.  et al. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197:711–23 [Google Scholar]
23. Crow YJ. 23.  2015. Type I interferonopathies: Mendelian type I interferon up-regulation. Curr. Opin. Immunol. 32:7–12 [Google Scholar]
24. Santer DM, Yoshio T, Minota S. 24.  et al. 2009. Potent induction of IFN-alpha and chemokines by auto-antibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J. Immunol. 182:1192–201 [Google Scholar]
25. Lovgren T, Eloranta ML, Kastner B. 25.  et al. 2006. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen—and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum 54:1917–27 [Google Scholar]
26. Martin DA, Elkon KB. 26.  2005. Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificity. J. Exp. Med. 202:1465–69 [Google Scholar]
27. Barrat FJ, Elkon KB, Fitzgerald KA. 27.  2016. Importance of nucleic acid recognition in inflammation and autoimmunity. Annu. Rev. Med. 67:323–36 [Google Scholar]
28. Niewold TB, Hua J, Lehman TJ. 28.  et al. 2007. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 8:492–502 [Google Scholar]
29. Chiche L, Jourde-Chiche N, Whalen E. 29.  et al. 2014. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 66:1583–95 [Google Scholar]
30. Crow YJ, Leitch A, Hayward BE. 30.  et al. 2006. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat. Genet. 38:910–16 [Google Scholar]
31. Gray EE, Treuting PM, Woodward JJ. 31.  et al. 2015. Cutting edge: cGAS is required for lethal autoimmune disease in the Trex1-deficient mouse model of Aicardi-Goutieres syndrome. J. Immunol. 195:1939–43 [Google Scholar]
32. Gao D, Li T, Li XD. 32.  et al. 2015. Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. PNAS 112:E5699–705 [Google Scholar]
33. Lee-Kirsch MA, Gong M, Chowdhury D. 33.  et al. 2007. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 39:1065–67 [Google Scholar]
34. Namjou B, Kothari PH, Kelly JA. 34.  et al. 2011. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun 12:270–79 [Google Scholar]
35. Klareskog L, Padyukov L, Ronnelid J. 35.  et al. 2006. Genes, environment and immunity in the development of rheumatoid arthritis. Curr. Opin. Immunol. 18:650–55 [Google Scholar]
36. Wallace DJ, Gudsoorkar VS, Weisman MH. 36.  et al. 2012. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat. Rev. Rheumatol. 8:522–33 [Google Scholar]
37. Shi C, Li H, Yang Y. 37.  et al. 2015. Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives. Mediat. Inflamm 2015:435713 [Google Scholar]
38. Hou LF, He SJ, Li X. 38.  et al. 2012. SM934 treated lupus-prone NZB×NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development. PLOS ONE 7:e32424 [Google Scholar]
39. Hou LF, He SJ, Li X. 39.  et al. 2011. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum 63:2445–55 [Google Scholar]
40. Gilad Y, Senderowitz H. 40.  2014. Docking studies on DNA intercalators. J. Chem. Inf. Model. 54:96–107 [Google Scholar]
41. Baldini G, Doglia S, Dolci S. 41.  et al. 1981. Fluorescence-determined preferential binding of quinacrine to DNA. Biophys. J. 36:465–77 [Google Scholar]
42. Busto N, Garcia B, Leal JM. 42.  et al. 2011. ACMA (9-amino-6-chloro-2-methoxy acridine) forms three complexes in the presence of DNA. Phys. Chem. Chem. Phys. 13:19534–45 [Google Scholar]
43. Chaires JB. 43.  1997. Energetics of drug-DNA interactions. Biopolymers 44:201–15 [Google Scholar]
44. Das S, Kundu S, Suresh Kumar G. 44.  2011. Quinacrine and 9-amino acridine inhibit B-Z and B-H_l form DNA conformational transitions. DNA Cell Biol 30:525–35 [Google Scholar]
45. van Dam L, Korolev N, Nordenskiold L. 45.  2002. Polyamine-nucleic acid interactions and the effects on structure in oriented DNA fibers. Nucleic Acids Res 30:419–28 [Google Scholar]
46. Zhang X, Wu J, Du F. 46.  et al. 2014. The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop. Cell Rep 6:421–30 [Google Scholar]
47. Deretic V. 47.  2011. Autophagy in immunity and cell-autonomous defense against intracellular microbes. Immunol. Rev. 240:92–104 [Google Scholar]
48. Fox R. 48.  1996. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 5:Suppl. 1S4–10 [Google Scholar]
49. Schultz KR, Bader S, Paquet J. 49.  et al. 1995. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease. Blood 86:4344–52 [Google Scholar]
50. Randow F, Munz C. 50.  2012. Autophagy in the regulation of pathogen replication and adaptive immunity. Trends Immunol 33:475–87 [Google Scholar]
51. Ratikan JA, Sayre JW, Schaue D. 51.  2013. Chloroquine engages the immune system to eradicate irradiated breast tumors in mice. Int. J. Radiat. Oncol. Biol. Phys. 87:761–68 [Google Scholar]
52. van Loosdregt J, Spreafico R, Rossetti M. 52.  et al. 2013. Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells. J. Allergy Clin. Immunol. 131:1443–46 [Google Scholar]
53. Lau CM, Broughton C, Tabor AS. 53.  et al. 2005. RNA-associated autoantigens activate B cells by combined B cell receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202:1171–77 [Google Scholar]
54. Vollmer J, Tluk S, Schmitz C. 54.  et al. 2005. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202:1575–85 [Google Scholar]
55. Kuznik A, Bencina M, Svajger U. 55.  et al. 2011. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186:4794–804 [Google Scholar]
56. Hacker H, Mischak H, Miethke T. 56.  et al. 1998. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 17:6230–40 [Google Scholar]
57. Lamphier M, Zheng W, Latz E. 57.  et al. 2014. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol. Pharmacol. 85:429–40 [Google Scholar]
58. Sun L, Wu J, Du F. 58.  et al. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339:786–91 [Google Scholar]
59. Zhang X, Shi H, Wu J. 59.  et al. 2013. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell 51:226–35 [Google Scholar]
60. Shu C, Li X, Li P. 60.  2014. The mechanism of double-stranded DNA sensing through the cGAS-STING pathway. Cytokine Growth Factor Rev 25:641–48 [Google Scholar]
61. Wallace DJ. 61.  1989. The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin. Arthritis Rheum. 18:282–96 [Google Scholar]
62. Rosman Z, Shoenfeld Y, Zandman-Goddard G. 62.  2013. Biologic therapy for autoimmune diseases: an update. BMC Med 11:88–100 [Google Scholar]
63. Crow YJ, Vanderver A, Orcesi S. 63.  et al. 2014. Therapies in Aicardi-Goutieres syndrome. Clin. Exp. Immunol. 175:1–8 [Google Scholar]
64. Wampler Muskardin T, Vashisht P, Dorschner JM. 64.  et al. 2015. Increased pretreatment serum IFN-beta/alpha ratio predicts non-response to tumour necrosis factor alpha inhibition in rheumatoid arthritis. Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2015-208001
65. Meunier B, Robert A. 65.  2010. Heme as trigger and target for trioxane-containing antimalarial drugs. Acc. Chem. Res. 43:1444–51 [Google Scholar]
66. Robert A, Dechy-Cabaret O, Cazelles J. 66.  et al. 2002. From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs. Acc. Chem. Res. 35:167–74 [Google Scholar]
67. Robert A, Meunier B. 67.  1998. Is alkylation the main mechanism of action of the antimalarial drug artemisinin?. Chem. Soc. Rev. 27:273–74 [Google Scholar]
68. Asawamahasakda W, Ittarat I, Pu YM. 68.  et al. 1994. Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrob. Agents Chemother. 38:1854–58 [Google Scholar]
69. Meshnick SR. 69.  2003. Artemisinin and heme. Antimicrob. Agents Chemother. 47:2712 [Google Scholar]
70. Wang J, Zhang CJ, Chia WN. 70.  et al. 2015. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. . Nat. Commun. 6:10111 [Google Scholar]
71. Uhlemann AC, Cameron A, Eckstein-Ludwig U. 71.  et al. 2005. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat. Struct. Mol. Biol. 12:628–29 [Google Scholar]
72. Sugioka Y, Suzuki M, Sugioka K. Nakano M.72.  1987. A ferriprotoporphyrin IX-chloroquine complex promotes membrane phospholipid peroxidation. A possible mechanism for antimalarial action. FEBS Lett 223:251–54 [Google Scholar]
73. Slater AF. 73.  1993. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol. Ther. 57:203–35 [Google Scholar]
74. Meshnick SR. 74.  1990. Chloroquine as intercalator: a hypothesis revived. Parasitol. Today 6:77–79 [Google Scholar]
75. Triglia T, Cowman AF. 75.  1994. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. PNAS 91:7149–53 [Google Scholar]
76. Yuthavong Y, Panijpan B, Ruenwongsa P. 76.  et al. 1985. Biochemical aspects of drug action and resistance in malaria parasites. Southeast Asian J. Trop. Med. Public Health 16459–72 [Google Scholar]
77. de Villiers KA, Marques HM, Egan TJ. 77.  2008. The crystal structure of halofantrine-ferriprotoporphyrin IX and the mechanism of action of arylmethanol antimalarials. J. Inorg. Biochem. 102:1660–67 [Google Scholar]
78. Friedman R, Caflisch A. 78.  2009. Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring. ChemMedChem 4:1317–26 [Google Scholar]